Winlevi, or clascoterone, is a topical medication approved for the treatment of acne and is being investigated for its potential use in addressing androgenetic alopecia, a common form of hair loss. It functions as an androgen receptor inhibitor, which means it can block the effects of androgens like dihydrotestosterone (DHT) that contribute to hair follicle miniaturization. Its relevance in hair biology lies in its ability to target the hormonal pathways involved in hair loss, offering a novel approach to treatment without the systemic side effects associated with oral medications. Key distinguishing characteristics include its topical application and its mechanism of action that specifically addresses androgen-related hair loss.